Serum IL-17 Correlated With Inflammatory Changes in Osteoarthritis and Rheumatoid Arthritis

Zagazig University120 enrolled

Overview

The total number of the included subjects was 120 in 3 equal groups (RA, OA and control). All subject was subjected to serum IL17 level measurement. MSK US (of both wrists, MCPs, PIPs and DIPs) was done to all patients in RA and OA groups. Disease activity was measured by disease activity score (DAS28) for RA patients. Visual analogue scale for pain (VAS) was obtained from patients in RA and OA groups. Functional assessment was done using health assessment questionnaire (HAQ) for RA patients and the Australian/Canadian (AUSCAN) Osteoarthritis Hand Index for OA patients

Study Type

OBSERVATIONAL

Enrollment

120

Conditions

Rheumatoid Arthritis (RA) and Osteoarthritis (OA)

Eligibility

Sex: ALLHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * A patient is considered having definite RA if he/she scores at least 6 points in the established classification system * A patient is considered having Hand OA if he /she Hand pain, aching, or stiffness plus 3 or 4 of hard tissue enlargement of 2 or more of 10 selected joints or hard tissue enlargement of 2 or more DIP joints or fewer than 3 swollen MCP joints, or deformity of at least 1 of 10 selected joints which are are the second and third distal interphalangeal (DIP), the second and third proximal interphalangeal, and the first carpometacarpal joints of both hands Exclusion Criteria: * Any subject with liver diseases, coronary artery diseases, kidney diseases or other inflammatory conditions was excluded from the study.

Locations (1)

Outcomes

Primary Outcomes

Clinical disease activity in Rheumatoid Arthritis (RA) and hand Osteoarthritis (OA) patients

During the whole course of the study, disease activity of the patients was measured by disease activity score (DAS28) for RA patients. Visual analogue scale for pain (VAS) was obtained from patients in RA and OA groups. Functional assessment was done using health assessment questionnaire (HAQ) for RA patients and the Australian/Canadian (AUSCAN) Osteoarthritis Hand Index for OA patients.

Time frame: 12 months

Secondary Outcomes

IL-17 serum levels in RA and OA patients

IL-17 will be measured by enzyme linked immunosorbent assay from collected serum samples from the study participants

Time frame: 2 weeks